Kaboré Jean Moïse Tanga, Siribié Mohamadou, Hien Denise, Soulama Issiaka, Barry Nouhoun, Baguiya Adama, Tiono Alfred B, Burri Christian, Tchouatieu André-Marie, Sirima Sodiomon B
Groupe de Recherche Action en Santé (GRAS), Ouagadougou 10248, Burkina Faso.
Swiss Tropical and Public Health Institute, Kreuzstrasse 2, 4123 Allschwil, Switzerland.
Trop Med Infect Dis. 2023 Mar 28;8(4):195. doi: 10.3390/tropicalmed8040195.
(1) Background: Effective malaria case management relies on World Health Organization (WHO) recommended artemisinin-based combination therapies (ACTs), but partial resistance to artemisinin has emerged and is spreading, threatening malaria control and elimination efforts. The strategy of deploying multiple first-line therapies (MFT) may help mitigate this threat and extend the therapeutic life of current ACTs. (2) Methods: A district-wide pilot quasi-experimental study was conducted, deploying three different ACTs at the public health facility (PHF) level for uncomplicated malaria treatment from December 2019 to December 2020 in the health district (HD) of Kaya, Burkina Faso. Mixed methods, including household and health facility-based quantitative and qualitative surveys, were used to evaluate the pilot programme. (3) Results: A total of 2008 suspected malaria patients were surveyed at PHFs, of which 79.1% were tested by rapid diagnostic test (RDT) with 65.5% positivity rate. In total, 86.1% of the confirmed cases received the appropriate ACT according to the MFT strategy. The adherence level did not differ by study segment ( = 0.19). Overall, the compliance level of health workers (HWs) with MFT strategy was 72.7% (95% CI: 69.7-75.5). The odds of using PHF as the first source of care increased after the intervention (aOR = 1.6; 95% CI, 1.3-1.9), and the reported adherence to the 3-day treatment regimen was 82.1%; (95% CI: 79.6-84.3). Qualitative results showed a high acceptance of the MFT strategy with positive opinions from all stakeholders. (4) Conclusions: Implementing an MFT strategy is operationally feasible and acceptable by stakeholders in the health systems in Burkina Faso. This study provides evidence to support the simultaneous use of multiple first-line artemisinin combination therapies in malaria-endemic countries such as Burkina Faso.
(1) 背景:有效的疟疾病例管理依赖于世界卫生组织(WHO)推荐的以青蒿素为基础的联合疗法(ACTs),但对青蒿素的部分耐药性已经出现并正在传播,这威胁到疟疾控制和消除工作。部署多种一线疗法(MFT)的策略可能有助于减轻这一威胁,并延长当前ACTs的治疗有效期。(2) 方法:在布基纳法索卡亚卫生区(HD)开展了一项全区范围的试点准实验研究,于2019年12月至2020年12月在公共卫生机构(PHF)层面部署三种不同的ACTs用于治疗非复杂性疟疾。采用混合方法,包括基于家庭和卫生机构的定量和定性调查,来评估该试点项目。(3) 结果:在PHFs共调查了2008名疑似疟疾病例,其中79.1%通过快速诊断检测(RDT)进行检测,阳性率为65.5%。根据MFT策略,总共86.1%的确诊病例接受了适当的ACTs。依从水平在各研究组间无差异(P = 0.19)。总体而言,卫生工作者(HWs)对MFT策略的依从率为72.7%(95%置信区间:69.7 - 75.5)。干预后将PHF作为首选医疗服务机构的几率增加(调整后比值比 = 1.6;95%置信区间,1.3 - 1.9),报告的对3天治疗方案的依从率为82.1%;(95%置信区间:79.6 - 84.3)。定性结果显示,MFT策略得到高度认可,所有利益相关者均给予积极评价。(4) 结论:在布基纳法索的卫生系统中,实施MFT策略在操作上是可行的,并且为利益相关者所接受。本研究提供了证据,支持在布基纳法索等疟疾流行国家同时使用多种一线青蒿素联合疗法。